

CORGANICS

Advancing Cannabinoid Education & Science Study

Primary Investigators

Kelsey Laird, PHD (California Institute of Integral Studies) Miroclav Backonja, MD (University of Washington) Chris Colwell, PHD (UCLA) Derek Loewy, PHD (Director of Behavioral Sleep at Scripps) Kate Taylor, PHD (UCLA)

Background

- Retail Cannabidiol (CBD) is broadly commercially available and recent surveys indicate that 1 in 5 Americans have taken CBD and 3 in 5 Americans see CBD as "valid medical therapy."*
- CBD that is broadly available via retail outlets is unregulated and third-party audits show that 73%–84% of retail CBD products are mislabeled or contain potentially. dangerous chemicals. **
- Many cancer patients seek alternative treatment solutions to mitigate treatment side effects and/or to treat pain, sleep disturbance, and anxiety.** - Few cancer patients who use Cannabidiol (CBD) discuss with their HCP. ***
- In a study of 100 cancer patients, up to 65% used CBD to mitigate uncontrolled negative symptoms.****
- Motivation to use CBD included pain (84%), anxiety (35%) and sleep (29%).
- Only 13% learned about CBD from a healthcare professional.

interference with general activity [G] on a scale of 0 to 30, with higher

• Regression analyses were run to assess score change through time in the

T-tests were completed to compare the mean change in outcome scores

Note: Any findings that were 'significant' meant that the likelihood of falsely rejecting the null

hypothesis that there were no differences between groups is very small (less than 5%).

scores signifying greater pain.

from baseline to study completion

full sample and by baseline condition severity.




01

System

Muscles 0

(CB1)

(CB1)



palpable difference in their quality of life

- 64% of participants with pain reported that

better" throughout the study period.

their pain symptoms were "better" or "much

through improved sleep quality.

(CB1 CB2)

Ø Objectives

 The objective is to evaluate the effectiveness of Corganics broad-spectrum Cannabidiol (CBD) in an Institutional Review Board (IRB)approved randomized controlled trial.

02

06

- · This report summarizes the results of Corganics Clinical Cannabidiol (CBD) Softgels in 208 participants and the impact on well-being, anxiety, pain, and sleep quality in participants over the course of 4 weeks.
- · For the trial, patients were recommended to take one 25 mg softgel once daily with food for the duration of the four-week trial.

Note: Corganics Clinical CBD products are available/dispensed exclusively via approved healthcare professionals



- Participants taking Corganics Clinical CBD Softgels saw "clinically meaningful" improvement in well-being, anxiety, sleep guality, and pain throughout the 4-week study period.
- Corganics Clinical Softgels, 25 mg were well tolerated, with 10% of participants reporting side effects, none were serious.
- Reported side effects were associated with the reasons why participants entered the trial (pain, anxiety, insomnia).
- · Largest improvements from baseline occurred in the first week of the study.
- Noticeable effect most often between 1 and 4 hours of taking product.
- · Participants most often reported that they took the product in the evening (43%), followed by the morning (29%), afternoon (24%), and early morning (4%).

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat or cure any disease.